EGRX
Eagle Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · PNK
HIGH
Data Confidence: 100.0%
Market Regime
Analysis pending
Today's Read
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile ...
2026-07-03
Full Daily Analysis
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$3M
Total market value of the company
1.56
Very cheap relative to earnings
0.07
Based on estimated future earnings — lower means cheaper
Rev Growth
-12.8%
Year-over-year revenue change
Profit Margin
4.6%
How much profit the company keeps from each dollar of revenue
4.9%
Return on equity — how efficiently it uses shareholder money
Recommendation
NONE
Consensus view from ? analysts covering this stock
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection,
https://www.eagleus.com
Country: United States Employees: 134 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
2,202.7% FAIL
Debt must be below 33% of total assets
Cash Ratio
466.8% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
$52.20
What our model estimates this business is worth per share
98.9%
Deep discount to fair value — significant undervaluation
Rating
AVOID
Overall assessment combining ethics, valuation, and quality
37.9th
Ranks in the top 62% of our 13,571 screened universe
Trading at $0 against a fair value of $52, a 100% discount. Fails ethical screen (Debt ratio). Ranks better than 72% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
ACCUMULATION
Smart money appears to be building positions quietly
1.374
Excellent risk-adjusted returns
0.0219
Modest edge detected — smaller position warranted
-0.620
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-62.0%
Historical annualised return based on price data
-100.0%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
0.66
Less volatile than the market — more defensive
52W High
$3.87
94% below the year high
52W Low
$0.00
24900% above the year low
Avg Volume
877
Average daily shares traded — higher means easier to buy and sell
3.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
4.2%
Low short interest — limited bearish positioning
N/A
Annual dividend as a percentage of the share price
$0.16
Earnings per share over the last 12 months
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
28.75
Heavy leverage — higher financial risk if revenues decline
2.16
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
1.51
Like current ratio but excludes inventory — stricter test
Gross Margin
69.8%
Revenue left after cost of goods — higher means pricing power
Operating Margin
15.9%
Profit from core operations before interest and tax
$38M
Positive — the business generates more cash than it spends
Revenue (TTM)
$258M
Total revenue over the last 12 months
Net Income
$12M
Profitable — the bottom line is positive
What If You'd Bought EGRX?
| Period |
Price Then |
Price Return |
Divs/Share |
$1,000 Became |
Total Return |
| 1 Month |
$0.38 |
+57.9% |
— |
$1,579 |
+57.9% |
| 2 Months |
$0.34 |
+76.0% |
— |
$1,760 |
+76.0% |
| 3 Months |
$0.34 |
+76.0% |
— |
$1,760 |
+76.0% |
| 6 Months |
$0.51 |
+17.7% |
— |
$1,177 |
+17.7% |
| 1 Year |
$2.25 |
-73.3% |
— |
$267 |
-73.3% |
| 2 Years |
$3.71 |
-83.8% |
— |
$162 |
-83.8% |
| 3 Years |
$18.88 |
-96.8% |
— |
$32 |
-96.8% |
| 5 Years |
$40.85 |
-98.5% |
— |
$15 |
-98.5% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
2026-07-03
ACCUMULATION $0.25
+0.0% Review #2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02
ACCUMULATION $0.25
Review #1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Latest Analysis — EGRX
Timestamped intelligence from our daily research pipeline
Want deeper analysis on Eagle Pharmaceuticals, Inc.?
Our framework analyses EGRX daily across 19 analytical perspectives — positioning, macro, sentiment, volatility, options, sector rotation, and more. Members get the read 24 hours before anyone else.
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-14